The approval has been granted for Spravato for use in conjunction with an oral antidepressant in adults with TRD, who have cycled through multiple treatments without relief. Janssen
The post FDA approves Janssen’s Spravato CIII nasal spray to treat depression appeared first on Pharmaceutical Business review.
Original Article: FDA approves Janssen’s Spravato CIII nasal spray to treat depression